| 36.81 -1.25 (-3.28%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.37 | 1-year : | 51.38 |
| Resists | First : | 40.55 | Second : | 43.99 |
| Pivot price | 39.06 |
|||
| Supports | First : | 35 | Second : | 29.12 |
| MAs | MA(5) : | 37.96  |
MA(20) : | 39.9 |
| MA(100) : | 32.09 |
MA(250) : | 34.85 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 33.6 |
D(3) : | 36.6 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 52.24 | Low : | 21.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RIGL ] has closed above bottom band by 17.2%. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.86 - 38.07 | 38.07 - 38.24 |
| Low: | 35.65 - 35.9 | 35.9 - 36.11 |
| Close: | 36.42 - 36.81 | 36.81 - 37.14 |
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Fri, 31 Jul 2026
Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 29 Jul 2026
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tue, 28 Jul 2026
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results - TradingView
Tue, 28 Jul 2026
Rigel schedules a live webcast for its Aug. 4 business update - Stock Titan
Mon, 27 Jul 2026
RIGL|Rigel Pharmaceuticals Inc|Price:39.045|Chg%:+0.545 - TradingKey
Mon, 27 Jul 2026
Rigel Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RIGL - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 93.6 (%) |
| Shares Short | 3,160 (K) |
| Shares Short P.Month | 3,460 (K) |
| EPS | 19.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.63 |
| Profit Margin | 121.5 % |
| Operating Margin | 20.2 % |
| Return on Assets (ttm) | 22.8 % |
| Return on Equity (ttm) | 174 % |
| Qtrly Rev. Growth | 10.3 % |
| Gross Profit (p.s.) | 13.15 |
| Sales Per Share | 16.2 |
| EBITDA (p.s.) | 6.86 |
| Qtrly Earnings Growth | -30.3 % |
| Operating Cash Flow | 79 (M) |
| Levered Free Cash Flow | 79 (M) |
| PE Ratio | 1.9 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 2.27 |
| Price to Cash Flow | 8.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|